PHS
KERX

Pekin Hardy Strauss’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Pekin Hardy Strauss’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,000
Closed -$217K – 197
2017
Q2 		$217K Hold
30,000
– – 0.03% 163
2017
Q1 		$185K Hold
30,000
– – 0.04% 166
2016
Q4 		$176K Hold
30,000
– – 0.02% 160
2016
Q3 		$159K Hold
30,000
– – 0.03% 154
2016
Q2 		$199K Hold
30,000
– – 0.04% 151
2016
Q1 		$140K Buy
30,000
+13,500
+82% +$53.9K 0.03% 153
2015
Q4 		$83K Buy
+16,500
New +$78.4K 0.02% 162

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Pekin Hardy Strauss's KERX Position: Q3 2017 in Review

Pekin Hardy Strauss sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2017, closing a stake of 30,000 shares — an estimated $217K sold.

Pekin Hardy Strauss first reported a position in KERX in Q4 2015 and held it in 7 quarters. The position peaked at $217K in Q2 2017. 132 funds tracked by Wall St. Rank hold KERX as of Q3 2017.

  • Pekin Hardy Strauss reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Pekin Hardy Strauss sold 30,000 Keryx Biopharmaceuticals Inc shares in Q3 2017, an estimated $217K.
  • Pekin Hardy Strauss first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 7 quarters.
  • Pekin Hardy Strauss's Keryx Biopharmaceuticals Inc position peaked at $217K in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2017.

Based on Pekin Hardy Strauss's 13F filing for Q3 2017, filed 3 Nov 2017.